Stefano Kim

N. Loménie, A. Lièvre, P. Laurent-Puig, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prognostic Value of Angiopoietin-2 for Death Risk Strati ﬁ cation in Patients with Metastatic Colorectal Carcinoma CancerEpidemiology,Biomarkers&Prevention

C. Borg, F. Ghiringhelli, D. Vernerey, 2015 .

[Immunotherapy: an emerging strategies against prostate castration resistant cancer].

F. Kleinclauss, X. Pivot, C. Borg, 2012, Bulletin du cancer.

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

L. Quéro, C. Maritaz, C. Borg, 2022, Frontiers in Oncology.

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma

C. Borg, B. De Bari, Stefano Kim, 2022, Frontiers in Oncology.

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer

C. Borg, F. Ghiringhelli, Thierry Nguyen, 2014, Cancer Chemotherapy and Pharmacology.

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

P. Laurent-Puig, C. Lepage, J. Emile, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

C. Borg, B. Buecher, O. Bouché, 2018, The Lancet. Oncology.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

A. Vincent-Salomon, I. Bièche, F. Bidard, 2018, Clinical Cancer Research.

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.

G. Piessen, F. Bibeau, F. Ghiringhelli, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Exposure‐response analysis of Raltitrexed assessing liver toxicity

C. Borg, Thierry Nguyen, D. Vernerey, 2020, British journal of clinical pharmacology.

Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial

C. Borg, Stefano Kim, T. André, 2022, Frontiers in Oncology.

Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2018 .

The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas

C. Borg, C. Mariette, F. Ghiringhelli, 2015, Journal of Hematology & Oncology.

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma

C. Borg, Thierry Nguyen, Stefano Kim, 2022, Frontiers in Oncology.

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2021, British Journal of Cancer.

A new anti-mesothelin antibody targets selectively the membrane-associated form

C. Borg, Stefano Kim, B. Royer, 2017, mAbs.

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment

R. Boidot, C. Borg, Stefano Kim, 2018, Oncotarget.

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

X. Pivot, C. Borg, Stefano Kim, 2013, Clinical colorectal cancer.

Prognostic value of baseline seric Syndecan‐1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

C. Borg, O. Bouché, F. Ghiringhelli, 2016, International journal of cancer.

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

C. Borg, E. Gherga, Thierry Nguyen, 2020, World journal of gastrointestinal oncology.

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

T. Mazard, Stefano Kim, M. Wagner, 2019, Cancer Imaging.

Third‐line systemic treatment for non‐small cell lung cancer

L. Trinquart, Stefano Kim, F. Bonnetain, 2014 .

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

C. Borg, B. Buecher, O. Bouché, 2022, European Journal of Cancer.

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.

C. Théodore, Stefano Kim, C. Papandreou, 2015, Clinical genitourinary cancer.

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma

C. Borg, C. Mariette, F. Fiteni, 2016, Cancer medicine.

Comparison of Molecular and Histologic Ultrastaging Methods in Sentinel Lymph Node Analysis from Clinical Stage II Colon Cancers

O. Deroo, C. Borg, Stefano Kim, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

C. Borg, B. Buecher, D. Vernerey, 2020, International journal of molecular sciences.

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer

F. Kleinclauss, X. Pivot, Thierry Nguyen, 2012, Clinical Medicine Insights. Oncology.

SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts

C. Borg, C. Ferrand, Thierry Nguyen, 2017, Oncoimmunology.

Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma

C. Borg, O. Bouché, F. Ghiringhelli, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Present and Future Research on Anal Squamous Cell Carcinoma

C. Borg, Stefano Kim, L. Cabel, 2021, Cancers.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

A. Lièvre, P. Laurent-Puig, H. Sokol, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

C. Borg, D. Vernerey, Stefano Kim, 2022, Frontiers in Oncology.

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

C. Borg, Thierry Nguyen, Stefano Kim, 2013, BMC Cancer.

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

C. Borg, B. Buecher, O. Bouché, 2020, Therapeutic advances in medical oncology.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

C. Borg, Stefano Kim, G. Meynard, 2021, European Journal of Cancer.

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

C. Borg, Thierry Nguyen, Stefano Kim, 2016, Clinical Medicine Insights. Oncology.

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.

C. Borg, M. Paillard, Stefano Kim, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study.

G. Deplanque, Stefano Kim, L. Mineur, 2020, Clinical colorectal cancer.

Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.

C. Borg, Thierry Nguyen, Stefano Kim, 2016, Clinical colorectal cancer.

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

R. Boidot, Stefano Kim, L. Arnould, 2023, Molecular Cancer.

Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.

C. Borg, C. Mariette, F. Fiteni, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).

C. Tournigand, Stefano Kim, J. Bachet, 2019, European journal of cancer.

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice

X. Pivot, C. Borg, Stefano Kim, 2021, Quality of Life Research.

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.

J. Bosset, C. Borg, Stefano Kim, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.

T. Mazard, Stefano Kim, D. Tougeron, 2024, European journal of cancer.

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

P. Morel, X. Pivot, P. Tiberghien, 2018, Oncoimmunology.